Rational development of a small-molecule activator of CK1γ2 that decreases C99 and beta-amyloid levels
V. H. Bustos, Y. K. Sunkari, A. Sinha, M. Pulina, A. Bispo, M. Hopkins, A. Lam, S. F. Kriegsman, E. Mui, E. Chang, A. Jedlicki, H. Rosenthal, M. Flajolet, P. Greengard, S. Sinha
This study identifies CK1γ2 as a therapeutic target for Alzheimer's disease by showing its activation reduces C99 and beta-amyloid levels through increased PS1-Ser367 phosphorylation.
bioRxiv · Apr 28, 2023Pharmacology & Toxicology